Gold tier: mechanically validated evidence, with its primary source.
7 evidence items · page 1 / 1
2,583 individualsThe study included 2583 SCD patients and healthy controls aged 5–21 years old in Mali, Senegal, Cameroon, Gabon and the Ivory Coast.
Cameroun · Côte d'Ivoire · Gabon · Mali · Sénégaldrépanocytosepublished 2019British journal of haematologyeurope_pmcdocument of 6 observations
3,627 patientsThe CADRE study included 3627 patients with sickle cell disease and 943 healthy controls.
Cameroun · Côte d'Ivoire · Gabon · Mali · Sénégaldrépanocytosepublished 2016CirculationPubMeddocument of 5 observations
3,699 patientsThe study involved 3699 sickle cell disease patients living in Mali, Senegal, Ivory Coast, Democratic Republic of Congo, Gabon and Cameroon.
Cameroun · Côte d'Ivoire · Gabon · Mali · Sénégaldrépanocytosepublished 2024British journal of haematologyeurope_pmcdocument of 10 observations
2,407 patientsIn Mali, Cameroon, and Ivory Coast, 2407 sickle cell disease patients aged 3 years old and over were included in the study.
Cameroun · Côte d'Ivoire · Malidrépanocytosepublished 2017Bloodeurope_pmcdocument of 4 observationsDOI 10.1182/blood-2016-12-755777
2,409 patientsAmong 2409 sickle cell disease patients in the CADRE cohort from Ivory Coast, Cameroon, and Mali, 1751 had the SS-Sβ0 phenotype and 658 had the SC-Sβ+ phenotype.
Cameroun · Côte d'Ivoire · Malidrépanocytosepublished 2015BloodOpenAlexdocument of 16 observations
3 %The prevalence of sickle cell disease was 3% in the population analyzed.
Côte d'IvoiredrépanocytoseHAL · Unilimdocument of 23 observations
27 %S and C genotypes were found in all the regions of Ivory Coast with the highest prevalence in the Northern region (S and C genotypes, 27%).
Côte d'IvoiredrépanocytoseHAL · Unilimdocument of 81 observations
Every row leads to its source document. The figure shown counts the VALIDATED observations it carries, never the extracted ones: the two differ on most documents. The exact source excerpt is not published, due to copyright constraints.